TC Biopharm (TCBP) Short Interest Ratio & Short Volume

Short interest is the volume of TC Biopharm shares that have been sold short but have not yet been covered or closed out. As of February 28th, investors have sold 49,400 shares of TCBP short. 176.43% of TC Biopharm's shares are currently sold short. Learn More on TC Biopharm's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 176.43% of TC Biopharm's floating shares are currently sold short.

TC Biopharm saw a decrease in short interest in the month of February. As of February 28th, there was short interest totaling 49,400 shares, a decrease of 61.5% from the previous total of 128,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

176.43% of TC Biopharm's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to TC Biopharm: Bio-Path Holdings, Inc. (0.13%), Petros Pharmaceuticals, Inc. (4.05%), Salarius Pharmaceuticals, Inc. (10.59%), Panbela Therapeutics, Inc. (0.00%), Hepion Pharmaceuticals, Inc. (0.12%), Biophytis S.A. (0.21%), Viracta Therapeutics, Inc. (0.04%), Trevena, Inc. (0.61%), Bon Natural Life Limited (66.10%), Vincerx Pharma, Inc. (0.05%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($23.74 billion), iShares 20+ Year Treasury Bond ETF ($10.75 billion), Strategy Inc ($6.56 billion), Apollo Global Management Inc. ($5.40 billion), Charter Communications, Inc. ($4.57 billion), AppLovin Corporation ($4.45 billion), Capital One Financial Corporation ($4.33 billion), Super Micro Computer, Inc. ($4.23 billion), Schlumberger Limited ($3.22 billion), and Royal Caribbean Cruises Ltd. ($3.06 billion). View all of the most shorted stocks.

Short selling TCBP is an investing strategy that aims to generate trading profit from TC Biopharm as its price is falling. TCBP shares are trading down $0.86 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for TC Biopharm occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of TCBP, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including TCBP, twice per month. The most recent reporting period available is February, 28 2025.